Taichung Veteran General Hospital
Welcome,         Profile    Billing    Logout  
 8 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Chieh-Liang
NCT04875260: Taiwan Center of Outcome and Resource Evaluation

Recruiting
N/A
600000
RoW
Critical Care
National Taiwan University Hospital
Critical Illness
07/40
12/40
Lin, Jin-Ching
NCT02363400: A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Enrolling by invitation
3
147
RoW
MEP, epirubicin, cisplatin, oral Tegafur-uracil, mitomycin-C
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Mackay Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Veterans General Hospital., Taichung Veterans General Hospital
Nasopharyngeal Carcinoma
12/19
12/22
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
NANORAY-312, NCT04892173 / 2021-002163-22: NBTXR3 With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Canada, Japan, US, RoW
NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy
Nanobiotix, Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
Lee, Teng-Yu
NCT05410496: Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients with Chronic HBV Infection

Active, not recruiting
4
52
RoW
Tenofovir Alafenamide 25 MG, TAF
Taichung Veterans General Hospital, Institute of Adherence to Medication
Safety Issues, Chronic Hepatitis B, Transplant Recipient
07/24
07/27
NCT03933384: Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

Recruiting
4
140
RoW
Tenofovir alafenamide, Vemlidy, Entecavir, Baraclude
Taichung Veterans General Hospital
Hepatitis B, Viral Hepatitis
12/27
12/30
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
NCT04180072: Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Active, not recruiting
N/A
51
RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital
Carcinoma, Hepatocellular
12/25
12/25
NCT05583006: Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B

Recruiting
N/A
60
RoW
tenofovir alafenamide (TAF), Vemlidy
Taichung Veterans General Hospital, Institute of Adherence to Medication
Patient Satisfaction, Drug Adherence, Efficacy, Self, Safety Issues
12/26
12/28
Yen, Jie-Ling
No trials found

Download Options